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Abstract 
LRRK2 is a 250kDa multidomain protein, mutations in which cause familial 
Parkinson’s disease. Previously, we have demonstrated that the R1441C 
mutation in the ROC domain decreases GTPase activity. Here we show that the 
R1441C alters the folding properties of the ROC domain, lowering its 
thermodynamic stability. Similar to small GTPases, binding of different guanosine 
nucleotides alters the stability of the ROC domain, suggesting that there is an 
alteration in conformation dependent on GDP or GTP occupying the active site. 
GTP/GDP bound state also alters the self-interaction of the ROC domain, 
accentuating the impact of the R1441C mutation on this property. These data 
suggest a mechanism whereby the R1441C mutation can reduce the GTPase 
activity of LRRK2, and highlights the possibility of targeting the stability of the 
ROC domain as a therapeutic avenue in LRRK2 disease. 
 
 
Abbreviations: DSF, differential scanning fluorimetry; CD, circular dichroism; GDP, guanosine 
diphosphate; GTP, guanosine triphosphate; LRRK2, leucine rich repeat kinase 2; ROC, Ras of 
complex proteins; PD, Parkinson’s disease 
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1. Introduction 
Leucine rich repeat kinase 2 (LRRK2) is a member of the ROCO family of 
proteins, defined by the presence of a ROC (Ras of complex proteins) domain 
followed by a domain of unknown function termed C-terminal of ROC, or COR 
[1]. In LRRK2, these domains are flanked towards the C- and N- termini 
respectively by leucine rich repeat (LRR) and kinase domains that give this 
protein its name, along with a number of protein/protein interaction domains [2]. 
The function of LRRK2 is unknown, but several mutations in this protein have 
been shown to cause autosomal dominant Parkinson’s disease (PD) [3, 4]. 
Overall, mutations in LRRK2 are the most common genetic cause of PD [5, 6].  
Due to their recent description and large size, very little is known about the 
biochemistry and function of the ROCO proteins. Studies focusing on the 
enzymatic activities of LRRK1 and LRRK2 have suggested that the GTPase 
activity of these proteins regulates their kinase activity, in a manner analogous to 
the interaction of small GTPases and associated kinases such as Ras and Raf 
[7-9]. Studies of mutations linked to Parkinson’s disease have shown that the 
kinase activity of LRRK2 is required for cytotoxicity associated with mutations 
[10-14]. However, while mutations in the kinase domain have a modest activating 
effect on kinase activity, mutations in the ROC domain of LRRK2 have not 
consistently been shown to affect kinase activity [15].  These same ROC domain 
mutations consistently disrupt the GTPase activity of the protein, which might 
lead to altered regulation of kinase activity, although the mechanistic basis for 
this is unclear [16-19]. These studies highlight the role of the enzymatic activities 
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of LRRK2 in the disease process, but the exact functional and spatial relationship 
between these two domains is unknown. 
We have previously demonstrated that the R1441C mutation decreases 
the GTPase activity of LRRK2 in the context of the full-length protein [16]. The 
crystal structure of LRRK2 ROC domain showed that the R1441 residue is distal 
to the active site of the protein and revealed that the R1441 residue sits at the 
interface between two constituent monomers in a dimeric structure [19]. This 
observation suggests that mutations at this residue could destabilize the 
interaction between the monomers, which might be the mechanism of enzymatic 
dysfunction. Consistent with this observation, we demonstrated that the ROC 
domain containing the R1441C mutation has a decreased ability to precipitate 
the full-length protein from cell lysates. However, the recent report of the crystal 
structure of a fragment of a ROCO protein from the prokaryote Chlorobium 
Tepidium consisting of the ROC and COR domains (the C. Tepidium ROCO 
protein does not contain a kinase domain) suggested that the role of R1441 is 
mainly inter-domain association. This alternative model implied that mutations at 
LRRK2 R1441 should not perturb the structure of the ROC GTPase domain 
itself, and instead acts to disrupt its interaction with the COR domain [20]. To 
further investigate the mechanism whereby the R1441C mutation disrupts 
ROC/ROC interactions and how it decreases the GTPase activity of LRRK2, we 
have used a variety of biophysical approaches including circular dichroism 
spectropolarimetry and differential scanning fluorimetry to assess the folding 
characteristics of the ROC domain and to test whether the R1441C mutation 
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alters these characteristics. 
 
2. Methods and materials 
 
2.1 Protein production and purification 
The ROC domain of LRRK2 was expressed and purified as previously reported 
[21]. Where only the wild type protein was used, the 6x polyhistidine tag was 
removed as described [21]. The R1441C mutant protein was expressed and 
purified as a 6xHis tagged fusion and was used to compare with the 6xHis 
tagged WT ROC protein. Attempts to remove the 6xhis tag from the mutant 
protein failed due to the drastically decreased stability of the protein (data not 
shown). Attempts to purify a GTP binding dead (K1347A) mutant form of the 
protein in a soluble form were also unsuccessful (data not shown). 
 
2.2 Circular dichroism 
Spectra were recorded with a Jasco J715 spectropolarimeter and measured at a 
protein concentration of 1 mg ml-1 with a 0.01 cm path length. The spectra are an 
average of 50 scans at 25°C, with background molecular ellipticity due to the 
buffer subtracted, in the presence of 4mM GDP. Analysis of protein stability was 
carried out with a protein concentration of 0.1 mg ml-1 and a 5mm path length 
(measurements were taken over a 10 nm bandwidth centered around 220 nm). 
Unfolding was carried out by melting over a temperature gradient from 25°C to 
85°C, ramping by 1° every minute. The ellipticity signal (h) was converted to 
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proportion of molecules in the native state αN, according to the relationship 
αN=(θ-θU)/(θN-θU), where θU and θN are the ellipticity signals for the unfolded and 
native states, respectively. Data were fitted to the Van’t Hoff function and the 
mid-point of thermal denaturation (Tm) defined as DH/DS. 
 
2.3 Differential scanning fluorimetry 
Thermal denaturation curves were also obtained using a Bio-Rad iCycler Single 
Wavelength Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, 
CA) and SYPRO Orange fluorescence dye (Invitrogen, Carlsbad, CA) with an 
excitation and emission wavelength of 490nm and 520nm, respectively.  The 
6xHis tagged ROC domain proteins (WT and R1441C) were subjected to a 
thermal gradient of 0.5°C increments from 23°–75°C.  The 50µl reaction 
consisted of 0.25mg/ml protein in 100mM HEPES, 150mM NaCl, 20mM MgCl2, 
pH 7.5 and a 2x SYPRO Orange final concentration diluted from concentrated 
stock. Guanine nucleotide ligands (GDP, GTP and GppNP) were added at a final 
concentration of 2mM accordingly. All experiments were performed with five 
replicates.  The Tm for each sample was calculated using the first derivative of 
the normalized fluorescence. 
 
2.4 Pulldown Assay 
Purified WT and R1441C 6xhis tagged ROC proteins were mixed with excess 
amounts of purified WT v5-tagged ROC. The protein mixtures were then 
incubated with Ni-NTA superflow resin for 1 hour at 4°C, in buffer A containing 
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20mM Tris, 500mM NaCl, 20mM Imidazole, 20 mM MgCl2, 10% Glycerol, pH 8.0. 
Different guanine nucleotide ligands (GDP, GTP and GppNP) were added to a 
final concentration of 2 mM accordingly. After extensive wash with buffer A, 
proteins were eluted from Ni-NTA. Co-purified proteins were analyzed by SDS-
PAGE and western blotting with biotinylated anti-V5 antibody (1:10000). 
Streptavidin conjugated HRP (1:2000) were used for developing the membrane. 
The SDS gels were scanned by CanonPI CS-U 3.8.1x scanner and the western 
blot was developed and scanned on Alpha Innotech FluoChem Instrument. The 
intensities of the bands were integrated and recorded using the software Kodak 
Digital Science 1D 3.0.2 analysis package. Pulldowns were replicated 3 times. 
 
3. Results 
To examine the secondary structure and folding properties of the ROC domain, 
we used two approaches - circular dichroism spectropolarimetry and differential 
scanning fluorimetry. CD analysis showed that the ROC domain forms ordered 
secondary structure in solution, with an absorbance spectrum suggestive of a 
predominantly α-helical fold with double minima at λ208 and 222 (figure 1A). This 
is in agreement with data from the crystal structure of the ROC domain, which 
revealed 46.5% α-helix and 21.6% β-pleated sheet, and with molecular modeling 
studies based upon the small GTPases [21]. Using graduated thermal melting, 
and following the percentage of folded protein using absorbance at 220nm with 
CD, the ROC domain was found to unfold in a co-operative manner (figure 1B). 
The mid-point of thermal denaturation or Tm determined by the loss of α-helical 
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structure was 41°C for the ROC domain in water in the absence of nucleotides. 
Using DSF to report the exposure of the hydrophobic core in the absence of 
nucleotides, the ROC domain unfolded with a very similar Tm of 39°C (figure 1C).  
As previously demonstrated with H-Ras, the presence of guanosine nucleotides 
has a major impact on the stability of the LRRK2 ROC domain (figure 1D), 
increasing the Tm to 52.5°C and 50.4°C in the presence of GDP and GDP 
respectively [22]. The R1441C mutation caused a destabilization of the ROC 
domain, decreasing the Tm by 4° in the presence of GDP and 5.5° in the 
presence of GTP as compared to the wild type domain (figure 1D and table 1).  
Based upon previous work examining LRRK2 self interaction using 
LRRK2 and fragments expressed in mammalian cell culture [23], we assessed 
ROC-ROC domain interactions between WT homodimers and WT/R1441C 
heterodimers with purified protein in solution, mimicking the situation in humans 
with heterozygous mutations. Using ROC domains with different epitope tags 
(6xHistag and V5), a significant decrease was observed in the interaction 
between mutant and WT domains (figure 2).  The interaction between WT and 
R1441C was lower still in the presence of GTP. 
 
4. Discussion 
We have previously shown that the R1441C mutation in the LRRK2 ROC domain 
results in a decrease in GTPase activity.  Based on the model of a dimeric ROC-
ROC structure, we predicted that the mutated residue sits at the interface in a 
dimeric structure for the ROC domain. In the current study, we sought to test the 
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hypothesis that the R1441C mutation decreases the thermodynamic stability of 
the ROC domain and to investigate the impact of guanosine nucleotides on the 
folding, stability and self-interaction of the ROC domain.  
 We assessed how the R1441C mutation and binding of guanosine 
nucleotides influence the folding properties of the ROC domain in solution. Using 
CD to assess secondary structure, we found that the ROC domain of LRRK2 
forms a predominantly α-helical secondary structure in solution, agreeing with 
data from crystallographic studies. Although of low resolution and describing only 
secondary structure, this is the first report of any structural information for LRRK2 
in solution. Using molecular ellipticity as a marker for percent folded protein in 
solution, we carried out thermal denaturation of the ROC domain, yielding a 
calculated Tm of 39°C. Using DSF to measure unfolded protein, we examined the 
impact of ligand binding and the R1441C mutation on the stability of the ROC 
domain. As previously shown with single domain GTPases, MgCl2 and 
guanosine nucleotides substantially increase the stability of the ROC domain, 
with GDP having a more pronounced impact than GTP [22]. This suggests, 
indirectly, an alteration in the three dimensional structural organization of the 
domain between the GDP and GTP bound states, and supports the thesis that 
the ROC domain is acting as a molecular switch [9]. This finding requires further 
investigation using high-resolution structural approaches. Intriguingly, the 
R1441C mutation consistently and significantly lowered the stability of the ROC 
in the presence of either GTP or GDP, suggesting that this mutation acts to 
destabilize the ROC domain. These data suggest that R1441 plays an important 
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role in the structural integrity of the GTPase domain itself, which is consistent 
with the crystal structural data of LRRK2 ROC dimer [21]. Due to the fact that the 
R1441 residue is not conserved between the ROCO proteins and the small 
GTPases such as a Ras and Rho, it is not possible to study or compare the 
impact of alterations at this residue in these proteins. We went on to examine 
ROC domain self-interaction in the light of data showing the impact of GDP and 
GTP on the stability of the ROC domain using differentially tagged ROC domain 
constructs. Results from these experiments demonstrate that the strength of 
interaction between differentially tagged ROC domain monomers is altered in the 
presence of GDP or GTP, that these have additive effects on stability of the ROC 
domain in the presence of the R1441C mutation. These data are consistent with 
structural information indicating that the R1441C mutation is distal from the GTP 
binding site and suggests that there are separate effects of guanine nucleotides 
and the R1441C mutation. These results also support previous data from our 
group looking at the interaction between full length LRRK2 from mammalian cell 
lysates and the ROC domain in the presence and absence of the mutation [21]. 
Both the stability data and the pulldown data suggest that there is an alteration in 
the three dimensional structure of the ROC domain based upon whether GDP or 
GTP is bound in the active site, again consistent with studies carried out on the 
small GTPases [24]. We are currently investigating this further using a variety of 
techniques. It is important to note that these studies need extending to larger, 
multi-domain fragments of LRRK2 in order to shed light on the nature and 
location of the interactions between the components of the LRRK2 dimer. To 
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date, we have not been able to purify fragments larger than the ROC domain that 
are stable in solution, and so such further studies wait upon overcoming this 
technical hurdle. 
In summary, our investigations into the folding, stability and self interaction 
properties of the ROC domain suggests a potential mechanism for dysfunction 
and loss of GTPase activity of the ROC domain based upon a decrease in 
stability associated with the R1441C mutation found in familial Parkinson’s 
disease. They represent the first description of a folding analysis of any of the 
domains of LRRK2.  Future experiments dissecting the relationship between 
stability and function may shed light on the underlying cause of LRRK2 
dysfunction linked to ROC domain mutations, and it will be important to extend 
these studies using larger fragments of LRRK2 and other mutations. These data 
also highlight the possibility of targeting the stability of the LRRK2 ROC domain 
as a potential therapeutic avenue to correcting the dysfunction of this domain, 
artificially reverting the destabilizing impact of the R1441C mutation. 
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Figure Legends 
 
Figure 1 A) CD analysis of the wild type ROC domain, displaying absorption 
spectra typical of a predominantly α-helical fold B, C) Thermal melt data from the 
ROC domain in the absence of ligand using CD (B) and DSF (C) to follow loss of 
structure D) DSF measurement of protein stability in the presence of GDP and 
GTP for wild type and R1441C ROC domain 
 
Figure 2 Pulldown analysis of the affinity of wild type and R1441C ROC domain 
for each other showing a significant decrease in the ability of ROC domain 
containing the R1441C mutation to precipitate the wild type domain. Analysis 
was carried out by two-way ANOVA with variant and ligand as separate 
variables, using a Bonferronni post hoc test. Indicated P values are **<0.01 and 
***<0.001. 
 
Table 1 Tm values for ROC +/- R1441C and GDP/GTP. Differences in stability 
due to presence of GDP or GTP for WT (P<0.005) and R1441C (P<0.005) were 
significant as assessed by Welch’s T-Test, with differences due to the presence 
of mutation (i.e. WT vs R1441C) in the case GDP (P<0.0001) or GTP 
(P<0.000005) also being significant. 
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